China Resources Double-Crane Pharmaceutical Co.,Ltd.
Shanghai Stock ExchangeTotal Valuation
China Resources Double-Crane Pharmaceutical Co.,Ltd. carries a market capitalization of 17.27B, placing it among publicly traded companies globally. Its enterprise value stands at 18.68B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 17.27B |
| Enterprise Value | 18.68B |
Share Statistics
China Resources Double-Crane Pharmaceutical Co.,Ltd. currently has 1.04B shares outstanding.
| Shares Outstanding | 1.04B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
China Resources Double-Crane Pharmaceutical Co.,Ltd. trades at a trailing price-to-earnings ratio of 15.33. The price-to-sales ratio is 2.34, and the price-to-book ratio stands at 1.61.
| PE Ratio | 15.33 |
| PS Ratio | 2.34 |
| PB Ratio | 1.61 |
| P/TBV Ratio | 2.04 |
| P/FCF Ratio | 47.01 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, China Resources Double-Crane Pharmaceutical Co.,Ltd. trades at an EV/EBITDA multiple of 13.60 and an EV/FCF ratio of 43.33. The EV/Sales ratio of 2.28 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 13.60 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.28 |
| EV / EBITDA | 13.60 |
| EV / EBIT | 13.60 |
| EV / FCF | 43.33 |
Financial Position
China Resources Double-Crane Pharmaceutical Co.,Ltd. maintains a current ratio of 2.67, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 12.99, indicating elevated leverage, while an interest coverage ratio of 55.43 demonstrates strong ability to service its debt obligations.
| Current Ratio | 2.67 |
| Quick Ratio | 1.02 |
| Debt / Equity | 12.99 |
| Debt / EBITDA | 1.23 |
| Interest Coverage | 55.43 |
Financial Efficiency
China Resources Double-Crane Pharmaceutical Co.,Ltd. posts a return on equity of 11.03 and a return on invested capital of 8.68.
| Return on Equity (ROE) | 11.03 |
| Return on Assets (ROA) | 7.09 |
| Return on Invested Capital (ROIC) | 8.68 |
| Return on Capital Employed (ROCE) | 9.11 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.33 |
Taxes
Over the trailing twelve months, China Resources Double-Crane Pharmaceutical Co.,Ltd. has paid 171.06M in income taxes, reflecting an effective tax rate of 11.74.
| Income Tax | 171.06M |
| Effective Tax Rate | 11.74 |
Stock Price Statistics
China Resources Double-Crane Pharmaceutical Co.,Ltd.'s stock has declined approximately -11.49548% over the past 52 weeks. The 50-day moving average sits at 17.10, while the 200-day moving average is 18.25.
| Beta (5Y) | N/A |
| 52-Week Price Change | -11.49548% |
| 50-Day Moving Average | 17.10 |
| 200-Day Moving Average | 18.25 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, China Resources Double-Crane Pharmaceutical Co.,Ltd. generated 8.19B in revenue and converted that into 1.25B in net income, yielding earnings per share of 1.24. EBITDA reached 1.37B, while operating income came in at 1.37B.
| Revenue | 8.19B |
| Gross Profit | 4.70B |
| Operating Income | 1.37B |
| Pretax Income | 1.46B |
| Net Income | 1.25B |
| EBITDA | 1.37B |
| EBIT | 1.37B |
| Earnings Per Share (EPS) | 1.24 |
Balance Sheet
China Resources Double-Crane Pharmaceutical Co.,Ltd. holds 3.07B in cash and equivalents against 1.69B in total debt, resulting in a net debt position of -928.17M. Total book value stands at 11.89B, with working capital of 5.04B providing operational flexibility.
| Cash & Cash Equivalents | 3.07B |
| Total Debt | 1.69B |
| Net Debt | -928.17M |
| Equity (Book Value) | 11.89B |
| Book Value Per Share | 11.51 |
| Working Capital | 5.04B |
Cash Flow
After subtracting -409.31M in capital expenditures, free cash flow totaled -409.31M - equivalent to -0.40 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -409.31M |
| Free Cash Flow | -409.31M |
| FCF Per Share | -0.40 |
Margins
China Resources Double-Crane Pharmaceutical Co.,Ltd. operates with a gross margin of 57.36, reflecting its pricing power and cost economics. The operating margin of 16.78 and net profit margin of 15.28 provide insight into operational efficiency.
| Gross Margin | 57.36 |
| Operating Margin | 16.78 |
| Pretax Margin | 17.80 |
| Profit Margin | 15.28 |
| EBITDA Margin | 16.78 |
Dividends & Yields
The company's payout ratio of 24.52 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.31 |
| Dividend Yield | N/A |
| Payout Ratio | 24.52 |
| Shareholder Yield | 2.64 |
| FCF Yield | 2.13 |
Stock Splits
China Resources Double-Crane Pharmaceutical Co.,Ltd.'s most recent stock split took place on August 16, 2018 with a 5:6 split ratio.
| Last Split Date | 8/16/2018 |
| Split Ratio | 5:6 |
Scores
China Resources Double-Crane Pharmaceutical Co.,Ltd. posts an Altman Z-Score of 4.66, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.66 |